Lionshead Wealth Management LLC Invests $716,000 in Pfizer Inc. (NYSE:PFE)

Lionshead Wealth Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,004 shares of the biopharmaceutical company's stock, valued at approximately $716,000.

Other hedge funds have also bought and sold shares of the company. Investor s Fiduciary Advisor Network LLC purchased a new position in Pfizer during the 4th quarter worth $664,000. Janus Henderson Group PLC boosted its holdings in shares of Pfizer by 80.7% in the 4th quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company's stock worth $25,434,000 after buying an additional 427,886 shares during the last quarter. JARISLOWSKY FRASER Ltd boosted its holdings in shares of Pfizer by 4.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 158,433 shares of the biopharmaceutical company's stock worth $4,203,000 after buying an additional 7,209 shares during the last quarter. KKM Financial LLC boosted its holdings in shares of Pfizer by 4.6% in the 4th quarter. KKM Financial LLC now owns 77,075 shares of the biopharmaceutical company's stock worth $2,045,000 after buying an additional 3,404 shares during the last quarter. Finally, Humankind Investments LLC boosted its holdings in shares of Pfizer by 18.3% in the 4th quarter. Humankind Investments LLC now owns 98,972 shares of the biopharmaceutical company's stock worth $2,626,000 after buying an additional 15,319 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.86 during trading hours on Wednesday, reaching $22.01. 59,282,663 shares of the company traded hands, compared to its average volume of 40,822,014. The company has a market cap of $125.13 billion, a P/E ratio of 15.61, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a 50-day moving average price of $23.89 and a 200 day moving average price of $25.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. The business's revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.81%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.